Sarah Abou Alaiwi

This study identifies MYBL2 as a master regulator of phenotypic plasticity in prostate cancer and shows CDK2 inhibition as a potential therapeutic strategy for MYBL2-driven tumors.

The paper identifies epigenomic signatures in sarcomatoid renal cell carcinoma (sRCC) that predict response to immune checkpoint inhibitors and are detectable in plasma, enabling non-invasive diagnosis.

This study identifies three germline variants associated with immune-related adverse events in patients treated with immune checkpoint inhibitors.

This study identifies PRMT1 as a critical regulator of AR signaling in prostate cancer through genome-scale CRISPR screening and shows its potential as a therapeutic target.